Oct 21 (Reuters) – AstraZeneca said on Wednesday the US Food and Drug Administration granted accelerated approval for its treatment for adults with immunoglobulin A nephropathy, a rare kidney disease
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)